---
title: "PTC Therapeutics, Inc. (PTCT.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PTCT.US.md"
symbol: "PTCT.US"
name: "PTC Therapeutics, Inc."
industry: "Biotechnology"
---

# PTC Therapeutics, Inc. (PTCT.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.ptcbio.com](https://www.ptcbio.com) |

## Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:14.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 70 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 97.54% |  |
| Net Profit YoY | 265.87% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -35.65 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.55B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.78B |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -124.24% | E |
| Profit Margin | 42.25% | A |
| Gross Margin | 45.05% | B |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 97.54% | A |
| Net Profit YoY | 265.87% | A |
| Total Assets YoY | 43.50% | A |
| Net Assets YoY | 85.23% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 236.68% | C |
| OCF YoY | 97.54% | A |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.79 | B |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 105.89% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - PTC Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-124.24%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "42.25%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "45.05%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "97.54%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "265.87%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "43.50%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "85.23%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "236.68%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "97.54%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.79",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "105.89%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | Abbvie (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.39 | 10/605 | 8.21 | 7.64 | 6.38 |
| PB | -35.65 | 550/605 | - | - | - |
| PS (TTM) | 3.12 | 71/605 | 3.97 | 3.08 | 2.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **15**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 47% |
| Overweight | 3 | 20% |
| Hold | 4 | 27% |
| Underweight | 0 | 0% |
| Sell | 1 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 68.93 |
| Highest Target | 124.00 |
| Lowest Target | 60.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/PTCT.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PTCT.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PTCT.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.